MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

HER3-targeted therapy

Search medical newsFind research, conditions and clinical updates
  • Home
  • HER3-targeted therapy
HER3 靶向药物 Ruzaltatug rezetecan 治疗 EGFR 突变晚期 NSCLC：HERON-Lung01 3 期中期分析优于化疗
Posted inClinical Updates Oncology

Ruzaltatug Rezetecan Versus Chemotherapy for EGFR-Mutated Advanced NSCLC Post-EGFR TKI Therapy: Interim Phase 3 HERON-Lung01 Analysis

Posted by By MedXY 11/12/2026
Ruzaltatug rezetecan, a HER3-directed antibody-drug conjugate, significantly improves progression-free survival over chemotherapy with manageable safety in EGFR-mutated advanced NSCLC progressing after EGFR TKI therapy.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Pain Perception in Parkinson’s Disease: Insights from Patient Narratives to Improve Care
  • Comparing Piezosurgery and Rotary Burs in Aesthetic Crown Lengthening: A Split-Mouth Randomised Trial
  • Ruzaltatug Rezetecan Versus Chemotherapy for EGFR-Mutated Advanced NSCLC Post-EGFR TKI Therapy: Interim Phase 3 HERON-Lung01 Analysis
  • Low-Level Pyuria and Antibiotic Prescribing for Suspected Urinary Tract Infection in Children
  • Exploring Blinatumomab as a Novel Therapy for Dermatomyositis and Refractory ANCA-Associated Vasculitis: Insights from a Two-Patient Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top